NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

Premier Doug Ford called the expansion of Eisai Inc. in Mississauga “a major milestone in strengthening our plan to build ...

And more pharma news updates from Pharmalittle.

CNW/ - Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, ...

Clinical Data Studio has supported 465 global studies since its launch in 2024, reducing data review cycles by up to 80% and ...

Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review. Hotspots ranked Start the day smarter ...

Eisai and Biogen hope the long-term data, presented at the Alzheimer’s Association International Conference, will boost global adoption of Leqembi, which was approved by the Food and Drug ...

Eisai estimated the number of U.S. patients eligible for the drug would reach around 100,000 within three years, increasing gradually from there over the medium to long term.

Eisai employs 1,680 people in the U.S. and more than 10,000 people around the world. At its Nutley headquarters, the company has almost 700 employees.

Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for ...

MISSISSAUGA — Eisai Limited, a research and development-based pharmaceutical company specializing in neurology and oncology, has expanded the footprint of its Canadian headquarters in Mississauga, ...